Clinical Trial Update: Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of Relma-cel followed by Tislelizumab for relapsed/refractory central nervous system lymphoma. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Diffuse Large B-cell Lymphoma
• Central Nervous System Lymphoma

Drugs mentioned

• Relma-cel
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Ruijin Hospital | Conditions: CNS Lymphoma | Phase 2 | Status: RECRUITING